Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 671,718 | 438,877 | 235,579 | 845,042 | 650,521 |
| Depreciation Amortization | 96,230 | 62,097 | 29,904 | 114,908 | 85,171 |
| Income taxes - deferred | -28,870 | -22,021 | -2,571 | -48,306 | -14,749 |
| Accounts receivable | -56,087 | -82,981 | -53,841 | -53,871 | -54,557 |
| Accounts payable and accrued liabilities | 2,347 | 3,802 | -4,450 | -557 | -6,799 |
| Other Working Capital | -124,503 | -67,135 | -81,416 | -72,429 | -114,252 |
| Other Operating Activity | 106,141 | 114,258 | 75,380 | 121,723 | 111,324 |
| Operating Cash Flow | $666,976 | $446,897 | $198,585 | $906,510 | $656,659 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,142 | 727 | 329 | 8,377 | 6,256 |
| PPE Investments | -91,667 | -63,578 | -30,273 | -133,631 | -101,075 |
| Net Acquisitions | -76,694 | -77,000 | -77,000 | N/A | N/A |
| Investing Cash Flow | $-167,219 | $-139,851 | $-106,944 | $-125,254 | $-94,819 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | -329,000 |
| Debt Repayment | -75,000 | N/A | N/A | -75,000 | N/A |
| Common Stock Issued | N/A | 26,241 | 20,879 | 47,034 | N/A |
| Common Stock Repurchased | -601,528 | -380,553 | -164,953 | -81,895 | -44,977 |
| Other Financing Activity | 31,237 | 0 | 0 | -332,135 | 33,825 |
| Financing Cash Flow | $-645,291 | $-354,312 | $-144,074 | $-441,996 | $-340,152 |
| Exchange Rate Effect | 238 | -5,076 | -4,066 | 2,126 | -2,538 |
| Beginning Cash Position | 453,932 | 453,932 | 453,932 | 112,546 | 112,546 |
| End Cash Position | 308,636 | 401,590 | 397,433 | 453,932 | 331,696 |
| Net Cash Flow | $-145,296 | $-52,342 | $-56,499 | $341,386 | $219,150 |
| Free Cash Flow | |||||
| Operating Cash Flow | 666,976 | 446,897 | 198,585 | 906,510 | 656,659 |
| Capital Expenditure | -91,667 | -63,578 | -30,273 | -133,631 | -101,075 |
| Free Cash Flow | 575,309 | 383,319 | 168,312 | 772,879 | 555,584 |